A multicenter retrospective study evaluating the safety and efficacy of combination of Brentuximab Vedotin Plus Bendamustine in pediatric patients with Relapsed/Refractory Hodgkin Lymphoma
Latest Information Update: 13 Jan 2021
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology